Related Experiment Videos
Hemolytic uremic syndrome in solid-organ transplant recipients
N Singh1, T Gayowski, I R Marino
1Infectious Disease Section, VA Medical Center, Pittsburgh, PA 15240, USA.
Summary
Post-transplant hemolytic uremic syndrome (HUS) is a serious complication after organ transplants. Early recognition and management of risk factors like immunosuppressants are crucial for patient survival and graft preservation.
Area of Science:
- Nephrology
- Transplant Surgery
- Immunology
Background:
- Post-transplant hemolytic uremic syndrome (HUS) is a rare but severe complication in organ transplant recipients.
- It presents with microangiopathic hemolysis, thrombocytopenia, and renal failure.
Observation:
- This study reviewed 91 cases of HUS in adult solid organ transplant recipients.
- HUS occurred in 2% of liver transplant patients in this series.
- Most cases (90%) were in renal transplant recipients, followed by liver (8%), lung (1%), and heart (1%).
Findings:
- Eighty percent of HUS cases occurred within 90 days post-transplantation.
- Calcineurin inhibitors (cyclosporine or tacrolimus) were implicated in 50% of renal and all non-renal transplant HUS cases.
- Infections were not a significant trigger for post-transplant HUS.
- Graft loss occurred in 43% of renal transplant recipients; renal failure necessitated transplantation or dialysis in lung and heart recipients.
- Overall mortality was 13%.
Implications:
- Physicians must be vigilant for post-transplant HUS, a life-threatening condition.
- Prompt identification and removal of risk factors, particularly immunosuppressive agents, are critical for management.
- Awareness of HUS is vital for improving outcomes in organ transplant recipients.